Scatter factor (SF) [hepatocyte growth factor] is a pleiotrophic cytokine that accumulates in tumors, where it may induce invasion, angiogenesis, and chemoresistance. We have studied the mechanisms by which SF and its receptor (c-Met) protect cells against the DNA damaging agent adriamycin (ADR) as a model for chemoresistance of SF/c-Met overexpressing tumors. Previous studies identified a PI3 kinase/c-Akt/Pak1/NF-κB cell survival pathway in DU-145 prostate cancer and MDCK epithelial cells. Here, we studied Src signaling pathways involved in SF cell protection. Src enhanced basal and SF-stimulated NF-κB activity and SF protection against ADR, in a manner dependent upon its kinase and Srchomology 3 domains; and endogenous Src was required for SF stimulation of NF-κB activity and cell protection. The ability of Src to enhance SF stimulation of NF-κB activity was due, in part, to its ability to stimulate Akt and IκB kinase (IKK-β) activity; and Src-mediated stimulation of NF-κB was due, in part, to a Rac1/MKK3/6/p38 pathway and was Aktdependent. SF caused the activation of Src and the Rac1 effector Pak1. Furthermore, SF induced activating phosphorylations of MKK3, MKK6, and p38 within the c-Met signalsome in a Src-dependent manner. The NF-κB inducing kinase (NIK) was found to act downstream of the TGF-β activated kinase 1 (TAK1) as a mediator of SF-and Src-stimulated NF-κB activity. Finally, the Src/Rac1/MKK3/6/p38 and Src/TAK1/NIK pathways exhibited cross-talk at the level of MKK3. These findings delineate some novel signaling pathways for SF-mediated resistance to ADR.
Scatter factor (SF) 1 [hepatocyte growth factor (HGF)] is a pleiotrophic cytokine that can stimulate cell motility, invasion, proliferation, morphogenesis, and differentiation in different cell types and contexts. It is postulated to play roles in development, tissue repair and remodeling, tumorigenesis, and angiogenesis (1) . Although SF was also identified as a "tumor cytotoxic factor" for hepatocarcinoma cells (2), in most cell types and contexts, SF inhibits apoptosis and promotes cell survival (3-6). We have studied the antiapoptotic activity of SF against cancer therapy agents, particularly DNA damaging agents (5) (6) (7) . These studies showed that SF protects epithelial, carcinoma, and glioma cells against adriamycin (ADR) [a topoisomerase IIα inhibitor], ionizing radiation [which causes breakage of the sugarphosphate backbone of DNA], cis-platinum [which cross-links DNA], and other agents. SF and its receptor c-Met are often over-expressed in tumors (8, 9) ; and their over-expression is associated with a poor prognosis in breast cancer and other tumor types (10) (11) (12) (13) . Thus, besides promoting invasion and metastasis, SF and c-Met over-expression in tumors may contribute to chemo/radioresistance.
Previous studies have identified some of the pathways through which SF protects epithelial and cancer cells against DNA damaging agents. The core protective pathway involves signaling from c-Met to PI3 kinase to the survival-promoting serine/threonine kinase c-Akt (5) (6) (7) . In addition to apoptosis inhibition, this pathway enhances the repair of DNA strand breaks (6, 7) . In this pathway, c-Akt acts upstream of p21-associated kinase 1 (Pak1) to stimulate NF-κB transcriptional activity and induce the expression of anti-apoptotic genes (TRAF2, cIAP1, and cIAP2) [7, 14] . Grb2-associated binder-1 (Gab1), a multi-substrate adaptor protein, and the tumor suppressor PTEN (phosphatase and tensin homolog) act upstream of c-Akt as negative regulators of SF protection (7, 14) .
Recombinant human two-chain SF was a gift from Dr. Ralph Schwall (Genentech, South San Francisco, CA). Adriamycin (doxorubicin) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye were obtained from the Sigma Chemical Co. (St. Louis, MO). The p38 inhibitor SB-202190 was purchased from CalBiochem (La Jolla, CA). Antibody reagents are described below.
c-Src, the homolog of the Rous sarcoma virus oncogene (v-src), is a member of a family of cytoplasmic tyrosine kinases. Src can function as a signal transducer for growth factor-stimulated cell migration, invasion, proliferation, survival, and tumorigenesis (15) . However, its roles in cell motility and proliferation are better understood than its role in cell survival. One mechanism by which v-src or activated c-Src mutants can stimulate cell survival (and other functions) is through a PI3 kinase/Akt pathway (16, 17) . Because it is frequently over-expressed and/or activated in human cancers, Src (and other Src family kinases) is a potential target for cancer therapy (18) .
Src and Src family kinases (eg., Fyn) interact with the activated c-Met receptor, in part, via a "multifunctional docking site" [ 1349 YVHVxxxYVNV] in the carboxy-terminus of the receptor (19). This interaction causes activation of Src (19, 20) . In some settings, Src can mediate activation of c-Met or activation of the SF promoter (21, 22) . Previously, we showed that Src can stimulate NF-κB activity and that inhibition of Src (eg., using the pharmacologic inhibitor PP1) blocks the ability of SF to stimulate NF-κB activity (14) . Here, we demonstrate that Src is required for SF cell protection; and we identify pathways by which Src stimulates NF-κB activity and cell survival.
EXPERIMENTAL PROCEDURES

Cell lines and culture
DU-145 human prostate cancer and Madin-Darby canine kidney (MDCK) epithelial cells were obtained from the American Type Culture Collection (Manassas, VA). The cells were cultured in DMEM containing 5% fetal calf serum, non-essential amino acids (100 mM), Lglutamine (5 mM), streptomycin (100 µg/ml), and penicillin (100 units/ml) [from BioWhittaker, Walkersville, MD]. The cells were grown at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
Reagents Expression vectors
Vectors encoding wild-type (wt), activated mutant (Y527F and Y530F), kinase-dead (K295R), and SH 3 domain mutant (D99N) chicken Src were provided by Dr. D. Shalloway (Cornell University, Ithaca, NY) [23] . The Src cDNAs were cloned into the pcDNA3 vector (Clontech, Mountain View, CA) using a PCR-based strategy; and the success of cloning was confirmed by sequence analysis. A dominant negative (DN) kinase-dead Akt mutant (K179A) in the pCIS2 vector was provided by Dr. M.J. Quon (NHLBI, NIH, Bethesda, MD) [24] . wt-PTEN and a phosphatase-defect mutant (C124S) in the pFLAG-CMV vector were provided by Dr. M. Georgescu (Rockefeller University, New York, NY) [25] . wt-MKK3, DN-MKK3 (S189A/T193), constitutively active (ca) MKK3 (S189E/T193E), wt-MKK6, DN-MKK6 (K82A), and ca-MKK6 (K82E) vectors were provided by Dr. R. Davis (University of Massachusetts Medical School, Worcester, MA) [26] . wt-Rac1 and DN-Rac1 (RacN17) in the pCEFL vector were provided by Dr. J. S. Gutkind (National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD). wt-NIK and DN-NIK cDNAs in the pcDNA3 vector were provided by Dr. D. Wallach (Weizmann Institute of Science, Rehovot, Israel) [27] . The DN-NIK vector encodes a kinase-dead mutant NIK with a KK → AA substitution within the ATP-binding domain. TAK1 and DN-TAK1 cDNAs in the pcDNA3 vector were provided by Dr. Hongbing Shu (National Jewish Medical Center, Denver, CO) [28] .
Transient transfections
Subconfluent proliferating cells were transfected overnight with the vector(s) of interest or the empty pcDNA3 vector (Invitrogen, Carlsbad, CA) [ 
Measurement of NF-κB transcriptional activity
The NF-κB-Luc reporter (Stratagene, La Jolla, CA) contains five copies of the NF-κB enhancer element upstream of a TATA box and luciferase. Briefly, subconfluent proliferating cells in 2-cm 2 wells were transfected overnight with 0.25 µg of NF-κB-Luc and 0.25 µg of each indicated vector, using Lipofectamine TM . The cells were washed, allowed to recover for several hours, treated ± SF (100 ng/ml) for 24 hr, and harvested for measurement of luciferase activity, using the Dual Luciferase Reporter Assay System (Promega, Piscataway, NJ). Relative transfection efficiency was determined using the Galacto-Star Mammalian Reporter Gene Assay System (Applied Biosystems, Foster City, CA) according to manufacturer's protocol. Luciferase values were means ± SEMs of quadruplicate wells.
Adriamycin treatment
Subconfluent proliferating cells in 6-well dishes were transfected overnight with the indicated vector(s) [5 µg of plasmid DNA per well], washed, and allowed to recover in fresh culture medium for several hours. The cells were harvested, inoculated into 96-well dishes in complete culture medium, allowed to attach overnight, washed, incubated ± SF (100 ng/ml x 48 hr) in serum-free DMEM, exposed to different doses of ADR [2 hr @ 37 o C], and post-incubated for 48 hr in fresh drug-free complete culture medium (again ± SF). They were then analyzed for cell viability using MTT assays. For each assay condition, cell viability was determined in 10 replicate wells.
MTT cell viability assay
This assay is based on the ability of viable mitochondria to convert MTT, a soluble tetrazolium salt, into an insoluble formazan precipitate, which is dissolved in DMSO and quantitated by spectrophotometry (29) . After ADR treatment as above, cells in 96-well dishes were tested for MTT dye conversion. The cell viability was calculated as the amount of MTT dye conversion relative to sham-treated control cells.
Measurement of Src kinase activity
Whole cell lysates were prepared; and equal aliquots of total cellular protein (500 µg) were immunoprecipitated with an anti-Src antibody, as described previously (23) . The precipitates were incubated with 10 µl of reaction buffer [20 mM PIPES, pH 7.0, 10 mM MnCl 2 , 10 µM Na 3 VO 4 ], 1 µl of freshly prepared acid-denatured enolase (Sigma) [5 µg of enolase plus 1 µl of 50 mM HCl incubated at 30°C for 10 min then neutralized with 1 µl of 1 M PIPES, pH 7.0], and 10 µCi of [ 32 P]-ATP. After 10 min of incubation at 30°C, reactions were terminated by addition of 2X SDS sample buffer, and samples were analyzed on 8% SDSpolyacrylamide gels. Serine and threonine phosphorylations were hydrolyzed by incubating the gel in 1 M KOH at 45°C for 30 min, followed by fixing in 45% methanol and 10% acetic acid for 30 min at 25 o C and vacuum drying for 2 hr at 80°C. Autoradiograms were produced and quantitated using a Storm PhosphoImager (Molecular Dynamics, Sunnyvale, CA).
Pak1 kinase activity
Rac1 activity was assessed by measuring the kinase activity of the Rac1 effector Pak1 (30) . DU-145 cells were harvested; and whole cell lysates were prepared (see below). Pak1 was immunoprecipitated from 150-250 µg of cell lysate in lysis buffer (see below) with a rabbit polyclonal anti-Pak1 antibody (AB3844, Chemicon) and dissolved in SDS-PAGE sample buffer. As a control, one-fifth of each IP sample was Western blotted for Pak1, using a polyclonal Pak1 antibody (N-19, 1:500 dilution, Santa Cruz). Pak1 kinase activity was determined using an in-gel kinase assay (31) . Briefly, the precipitates were run on 10% SDS-polyacrylamide gels containing 0.5 mg/ml of myelin basic protein (MBP). Proteins in the gel were then renatured; and their kinase activity toward MBP was initiated by soaking the gels in kinase buffer containing 25 µCi/ml of [ 
IKK-β kinase activity
IKK-β kinase activity was measured using the HTScan TM IKK-beta Kinase Assay Kit (Cell Signaling Technology, Inc., Danvers, MA). This assay measures the ability of a cell lysate to phosphorylate a biotinylated IκB-α (Ser32) substrate peptide. A phospho-IκB-α (Ser32/36) specific mouse monoclonal is used to detect the phosphorylated substrate peptide. For assay standardization, the kit provides an active GST-IKK-β kinase fusion protein. Each assay condition was tested in five replicate wells; and IKK-β activity was expressed relative to untransfected, non-SF treated controls.
Immunoprecipitation (IP)
Subconfluent proliferating DU-145 cells were washed and incubated in serum-free DMEM ± SF (100 ng/ml) for 20 min. The cells were then scraped into lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 10% glycerol, 1% NP-40, and protease inhibitor cocktail set I (Calbiochem)] (1 ml per 100-mm dish). The lysates were incubated for 30 min at 0 o C and centrifuged at 17,000 x g for 15 min at 4°C. After protein quantitation, 500 µg of supernatant protein was pre-cleared for 1 hr by addition of Bio-Mag beads (Qiagen) and incubated with 5 µg of IP antibody plus Bio-Mag beads at 4°C overnight. The IP antibodies were rabbit polyclonal Src antibody (#sc-6096, Santa Cruz) or rabbit polyclonal c-Met antibody (#ab14570, Abcom, Inc., Cambridge, MA). The beads were washed four times with 0.5 ml of lysis buffer; and 1x loading buffer [25 mM Tris-HCl (pH 6.5), 5% glycerol, 1% SDS, 1% 2-mercaptoethanol, and 0.05% bromphenol blue] was added. The samples were boiled for 3 min before Western blotting.
Western blotting
After treatment, the cells were collected using trypsin, washed twice with PBS, and pelleted by centrifugation. The pellet was resuspended in RIPA buffer, placed on ice for 30 min, and spun for 15 min at 14,000 rpm at 4°C to remove the insoluble material. Western blotting was performed as described earlier (14) . Briefly, aliquots of cell protein (50 µg) were electrophoresed in 4-20% SDS-polyacrylamide gradient gels and transferred to nitrocellulose membranes. Alternatively, immunoprecipitated proteins (see above) were subjected to SDS-PAGE and transferred to nitrocellulose membranes.
The membranes were blotted using the following primary antibodies: phospho-Akt 
Anoikis assays
Assays of anoikis (apoptotic cell death triggered by detachment of the cell from its substratum) were performed by a modification of previously described protocols (3,32). Briefly, subconfluent proliferating MDCK cells were transiently transfected overnight with the indicated vector(s), washed, and allowed to recover for several hr. Plastic 100-mm Petri dishes were coated with 8 ml of a 10 mg/ml solution of polyhydroxyethyl-methacrylate (poly-HEMA), a polymer to which the cells cannot attach. The transfected cells were then suspended using trypsin, counted, and inoculated into poly-HEMA coated dishes (3 x 10 6 cells per dish) in cell growth medium ± SF (100 ng/ml). At 48 hr after inoculation, the cells were harvested; and any cell aggregates were dispersed using trypsin. Cell viability was determined by trypan dye exclusion analysis (33) . For each dish, at least 200 cells were counted. Each assay was performed in duplicate; and the results represent the means ± ranges from two independent experiments.
Statistical analyses
Where appropriate, comparisons were made using the two-tailed Student's t-test.
RESULTS
Src modulates SF stimulation of NF-κB transcriptional activity and IKK-β kinase activity.
We tested the role of Src in SF stimulation of NF-κB activity, using a set of Src mutant expression vectors. DU-145 or MDCK cells were transiently transfected with different vectors plus the NF-κB-Luc reporter; treated ± SF (100 ng/ml) for 24 hr; and assayed for luciferase activity. Typically, SF caused a (50-70)-fold increase in NF-κB activity. With SF present, wt-Src caused a (3-4)-fold increase in NF-κB activity (P < 0.001, two-tailed t-test) beyond that observed with SF alone or (SF+empty vector) [ Fig. 1A ]. Two activated Src mutants (Y527F and Y530F) caused increases in SF-stimulated NF-κB activity (P < 0.001) similar to wt-Src. In contrast, a DN kinase-dead Src mutant (K295R) [23] abrogated basal and SFstimulated NF-κB activity; and an SH 3 domain mutant (D99N) [34] reduced the SF-stimulated NF-κB activity to about 20% of that due to SF alone (P < 0.001). DU-145 and MDCK cells gave similar responses.
In the absence of SF, wt-Src and the activated mutants stimulated NF-κB activity by about (5-6)-fold, compared with untransfected or empty vector (pcDNA3)-transfected controls (P < 0.001) [Fig. 1A ]. The K295R (DN) and D99N mutants severely attenuated or abrogated the basal NF-κB activity in the absence of SF (P < 0.001). Because DN-Src might have other effects than inhibition of Src, we also tested the effects of Src knockdown. A control-siRNA had no effect on basal or SF-stimulated NF-κB activity; but SrcsiRNA caused a ≥ 10-fold reduction in SFstimulated as well as basal NF-κB activity (P < 0.001) [ Fig. 1B ]. These findings suggest that Src stimulates basal and SF-induced NF-κB activity in a manner requiring its kinase and SH 3 domains and that Src is required for SF-induced NF-κB activity.
IκB kinase (IKK) stimulates NF-κB activity by causing phosphorylation and degradation of IκB proteins, the cytoplasmic inhibitors of NF-κB (35) . We tested the effects of Src on the kinase activity of IKK-β, the catalytic subunit, which phosphorylates IκB-α and IκB-β on serine residues. SF caused a 5-fold increase in IKK-β activity in DU-145 cells (P < 0.001) [ Fig.  1C ]. wt-Src, Y527F, and Y530F enhanced IKK-β activity ≥ 6-fold beyond that due to SF alone or (SF+pcDNA3) [P < 0.001]; while K295R and D99N blocked the SF-stimulated increases in IKK-β activity (P < 0.001). Without SF, wt-Src caused a 4-fold increase in IKK-β activity (P < 0.001); while K295R and D99N inhibited IKK-β activity (Fig. 1C) . These findings suggest that Src contributes to SF-stimulated (and basal) IKK-β.
Effects of SF and Src mutant proteins on Src activity. We performed IP-kinase assays using enolase as the substrate (23) DN-Src (K295R) had no effect on survival in the absence of SF but severely attenuated the SF-stimulated survival at all ADR doses (P < 0.01) [ Fig. 2C ]. Src mutants Y527F (Fig. 2D ) and Y530F ( Fig. 2F ) caused modest increases in survival without SF but caused stronger increases in SF-stimulated survival (P < 0.01 at all ADR doses except 1 µM). The SH 3 mutant (D99N) did not alter basal cell survival but strongly attenuated SF-stimulated survival (P < 0.01) [ Fig. 2E ]. These findings suggest that the Src kinase and SH 3 domains are required for protection by SF and the SF protection pathway can be further activated by exogenous Src. We tested the role of endogenous Src in modulating survival by pre-treating the cells with Src vs control siRNA. With control-siRNA, SF protected the cells against ADR as expected, while Src-siRNA abrogated SF protection (P < 0.001) [ Fig. 2G ]. Without SF, the survival of cells treated with Src-siRNA was similar to or slightly less than that of cells treated with control-siRNA. These findings suggest that Src is required for SF protection against ADR.
Src-stimulated NF-κB activity is Akt-dependent.
Here, DU-145 or MDCK cells were transfected with wt-Src and/or DN-Akt and tested for SF stimulation of NF-κB activity. DN-Akt nearly abrogated NF-κB activity in the presence of SF alone; and in the presence of (SF+wt-Src), it reduced NF-κB activity to below that found with SF alone (P < 0.001) [Fig. 3A] . PTEN, an inositol polyphospate-3-phosphatase, acts upstream of Akt to block its activation (35) . We tested the effects of wt-PTEN and a phosphatase-defective mutant (mut-PTEN) on Src/SF-stimulated NF-κB activity. wt-PTEN reduced SF-stimulated NF-κB activity to about 30% of that with SF alone (P < 0.001), while mut-PTEN caused modest increases in NF-κB activity [ Fig. 3B ]. wt-Src caused a (5.6-7.1)-fold increase in SF-stimulated NF-κB activity (P < 0.001), while its co-expression with wt-PTEN reduced the NF-κB activity to about that due to SF alone (P < 0.001). SF-stimulated NF-κB activity was slightly higher in the presence of (wtSrc+mut-PTEN) than wt-Src alone. Consistent with these findings, wt-PTEN abrogated the ability of wt-Src to enhance survival of ADR-treated MDCK cells; and in the presence of SF, cells transfected with (wt-Src+wt-PTEN) showed lower survival than cells transfected with empty vector only (data not shown). These findings suggest that the ability of Src to stimulate NF-κB activity and cell protection is dependent upon Akt.
Role of Src in Akt activation.
To test the ability of Src to modulate activating phosphorylations of Akt, DU-145 cells were transfected with different Src vectors, treated ± SF (20 min), and Western blotted using phospho-specific antibodies. Without SF, there was little phospho-Akt in untransfected or vector-transfected cells. wt-Src and both active Src mutants induced Akt phosphorylation on serine-473 and threonine-309 (Fig. 3C, left) and also enhanced the SF-stimulated Akt phosphorylation on both sites (Fig. 3C, right) ; while K295R and D99N abrogated the SF-induced phosphorylation. These findings suggest that Src over-expression can activate Akt and Src activity is required for Akt activation by SF.
Role of MKK3/6/p38 pathway in Src stimulation of NF-κB activity. Previously, we showed that a MKK3/6/p38 pathway contributes to SF stimulation of NF-κB activity (see Discussion). Here, we tested the ability of different Src proteins to regulate this pathway. We used an antiphospho-p38 (threonine-180/182) antibody to detect activated p38 (26) . wt-Src and the active mutants (but not the inactive mutants) enhanced the basal phospho-p38 levels, while total p38 levels were unchanged (Fig. 4A, left) . Each Src protein was well-expressed. A 20 min exposure to SF stimulated phospho-p38 formation; and the three active Src proteins enhanced SF-stimulated p38 phosphorylation (Fig. 4A, right) . These findings suggest roles for Src in basal and SFstimulated p38 activation. MKK3 and MKK6 are selective p38 activators (38) . We tested the requirement for MKK3/6 in Src stimulation of NF-κB activity, using DN expression vectors. Here, we found that expression of a DN-MKK3 or DN-MKK6 protein strongly inhibited both (wtSrc+SF)-stimulated and wt-Src-stimulated NF-κB activity (P < 0.001) [ Fig. 4B ].
Next, we tested if Src is required for MKK3/6 mediated NF-κB activation. wt-MKK3 and wt-MKK6 enhanced SF-stimulated NF-κB activity by (3-4)-fold in DU-145 and MDCK cells (P < 0.001). As expected, DN-Src (K295R) blocked SF-stimulated NF-κB activation (Fig.  4C) . However, wt-MKK3 and wt-MKK6 each rescued the inhibition of NF-κB activity by DNSrc (P < 0.001). In fact, DN-Src had little or no effect on NF-κB activity in the presence of wt-MKK3/6 ± SF. These findings suggest that MKK3/6 act downstream of Src to activate NF-κB, in part, through p38. We further found that DN-MKK3 and DN-MKK6 inhibited basal and SF/wt-Src/(SF+wt-Src)-stimulated IKK-β activity (Fig. 4D) .
Role of MKK3/6 in stimulation of NF-κB activity by Rac1. Several studies suggest that Rac1, a member of the Ras superfamily of small GTPases, can activate MKK3/MKK6/p38 signaling (25, 39) . We found that exogenous wt-Rac1 enhanced SFstimulated NF-κB activity by (3-4)-fold in DU-145 and MDCK cells (P < 0.001); and coexpression of DN-MKK3 or DN-MKK6 strongly attenuated the (SF+wt-Rac1)-stimulated NF-κB activity (P < 0.001) [Fig. 5A ]. Next, we tested if wt-MKK3 or wt-MKK6 could stimulate NF-κB activity in cells co-transfected with a DN-Rac1 (RacN17). DN-Rac1 blocked SF-stimulated NF-κB activity but was unable to block NF-κB activity stimulated by wt-MKK3/6 ± SF (Fig. 5B) . These findings suggest that Rac1 acts upstream of MKK3/6 in the NF-κB activation pathway.
We tested the role of p38 in Rac1 and Src stimulated IKK-β activity, using a selective p38 inhibitor (SB202190). wt-Rac1 and wt-Src enhanced SF-stimulated IKK-β activity by (4-5.4)-fold and stimulated basal IKK-β activity to a lesser extent (Fig. 5C ). SB202190 abrogated the SFstimulated IKK-β activity and reduced (SF+wt-Rac1) and (SF+wt-Src) stimulated IKK-β activity to less than that of SF alone (P < 0.001). SB202190 also inhibited the wt-Rac1 and wt-Src stimulated IKK-β kinase activity in the absence of SF. The expression of wild-type and DN MKK proteins is shown in Fig. 5D (right panels). Like DN-Src, DN-Rac1 blocked SF-induced p38 phosphorylation; and wt-Rac1 induced p38 phosphorylation in the absence of SF (Fig. 5D , left panels). These findings suggest that p38 is required for IKK-β activation by SF, Rac1, and Src, individually or in combination.
Relationship of TAK1/NIK to Src and MKK3/6 pathways of NF-κB activation. TAK1 (TGF-β activated kinase 1) is a MAPKKK family protein that can stimulate NF-κB activity by activating NIK (NF-κB inducing kinase), MKK3, and MKK6 (40, 41) . We tested the roles of TAK1 and NIK in SF/Src mediated NF-κB activation. wt-TAK1 and wt-NIK enhanced SF-stimulated NF-κB activity by ≅ 3-and 6-fold, respectively (P < 0.001) and stimulated basal NF-κB activity to a lesser extent (Fig. 6A) . DN-NIK inhibited stimulation of NF-κB activity by SF alone and (SF+wt-TAK1) (P < 0.001) [Fig. 6B ]. DN-TAK1 also inhibited basal and SF-stimulated NF-κB activity (P < 0.001) but had little effect on wt-NIK-or (SF+wt-NIK)-stimulated NF-κB activity (Fig. 6C) . Expression of the exogenous TAK1 and NIK proteins is shown in Fig. 6B (right panels) . Consistent with these data, NIK-siRNA inhibited SF-stimulated NF-κB activity and abrogated the ability of wt-TAK1 to enhance SF-induced NF-κB activity (P < 0.001) [ Fig. 6D ], suggesting that NIK is downstream of TAK1 and contributes to SF-stimulated NF-κB activity.
. Next, we tested the roles of TAK1/NIK in (SF+Src)-induced NF-κB activation. Again, DN-NIK (Fig. 6E) and DN-TAK1 (Fig. 6F ) inhibited basal and SF-stimulated NF-κB activity, but the degree of inhibition was greater than in the experiments shown in Figs. 6B-C. Both DN-NIK and DN-TAK1 blocked (SF+wt-Src)-stimulated NF-κB activity (P < 0.001); and both DN vectors reduced the NF-κB activity due to wt-Src alone to about the basal activity without wt-Src or SF (P < 0.001). In the absence of SF, DN-Src failed to inhibit the ability of wt-TAK1 (Fig. 6G ) or wt-NIK (Fig. 6H) to stimulate NF-κB activity. However, DN-Src blocked (SF+wt-TAK1)-and (SF+wt-NIK)-stimulated NF-κB activity. Stated otherwise, neither wt-TAK1 nor wt-NIK rescued the inhibition of SF-stimulated NF-κB activity by DN-Src. These findings suggest that while Src is upstream of TAK1/NIK, SF stimulates an additional Src-dependent but TAK1/NIKindependent pathway(s) essential for SF activation of NF-κB.
Next, we tested if TAK1/NIK and MKK3/6 interact in regulating NF-κB. As above, DN-MKK3 and DN-MKK6 inhibited and wt-TAK1 and wt-NIK enhanced basal and SFinduced NF-κB activity. The combination (wt-TAK1+DN-MKK3) reduced basal and SFstimulated NF-κB activity to levels similar to or lower than those observed in the absence of wt-TAK1 (Fig. 7A) . Similar results were observed for the combination (wt-NIK+DN-MKK3) [ Fig. 7B ]. DN-MKK6 also inhibited wt-TAK1 and wt-NIK stimulated NF-κB activity; but to a lesser extent than did DN-MKK3.
We performed the converse study using wt-MKK3/6 and siRNAs to knock down TAK1 or NIK. TAK1-and NIK-siRNA strongly inhibited basal and SF-stimulated NF-κB activity but had only a modest effect on wtMKK3-stimulated activity (Figs. 7C and 7D) . The siRNAs caused a moderate reduction of wtMKK6-stimulated NF-κB activity (± SF); but neither siRNA reduced NF-κB activity to close to that observed in the absence of wt-MKK6. These findings suggest that MKK3 acts, in part, downstream of TAK1/NIK to stimulate NF-κB signaling. We note that while DN-MKK3 inhibited NF-κB under all conditions, wt-TAK1 and wt-NIK were still able to stimulate (partially rescue) NF-κB activity in the presence of DN-MKK3, suggesting that TAK1/NIK also stimulate NF-κB by an MKK3-independent mechanism. The relationship between TAK1/NIK and MKK6 is less clear than for MKK3, but our results suggest that TAK1 and NIK signal to NF-κB by MKK6-dependent and MKK6-independent pathways.
Association of MKK3/6 and p38 with Src and cMet. DU-145 cells were incubated ± SF (100 ng/ml x 20 min) and subjected to IP-Western blotting using IP antibodies against Src or Met. We found that Src and Met associated with each other in bi-directional IPs in a SF-independent manner (Fig. 8A) . While the total quantity of Src in the Met IP and vice versa did not change, SF increased the amount of phosphorylated Src associated with Met and vice versa. Both Src and Met associated with MKK3, MKK6, and p38; and the levels of phosphorylated MKK3, MKK6, and p38 in the Src and Met IPs were increased by SF. These findings suggest that SF causes activation of Src, MKK3, MKK6, and p38 within the c-Met signalsome.
To test the dependence of MKK3/6/p38 phosphorylations upon Src, DU-145 cells were pre-treated with Src-vs control-siRNA, incubated ± SF, and Western blotted. Src-siRNA knocked down Src protein levels but had little effect on the total levels of Met, MKK3/6, or p38 (Fig. 8B) . SF induced phosphorylation of Src, MKK3, MKK6, and p38 in the control-siRNA treated cells but not the Src-siRNA treated cells. SF was still able to induce Met phosphorylation in Src-siRNA treated cells. These findings suggest that Src is required for activation of the MKK3/6/p38 pathway by SF but is not required for Met activation; and they suggest a SF/c-Met/Src/MKK3/6/p38/NF-κB activation scheme.
Src acts upstream of Rac1 in NF-κB activation.
Here, we tested the ability of DN-Rac1 to block wt-Src-stimulated NF-κB activity and vice versa.
Consistent with earlier findings, SF stimulated NF-κB activity by 70-fold in DU-145 and MDCK cells; and wt-Src enhanced the SF-stimulated NF-κB activity by about 3.5-fold (Fig. 9A) . DN-Rac1 blocked the increase in NF-κB activity due to SF alone and reduced the NF-κB activity of cells treated with (SF+wt-Src) to below that due to SF alone (P < 0.001). DN-Rac1 also inhibited basal and wt-Src-stimulated NF-κB activity in the absence of SF. In contrast, DN-Src did not block the ability of wt-Rac1 to stimulate NF-κB activity in the presence or absence of SF (Fig. 9B) . As positive controls, DN-Src inhibited basal and SFstimulated NF-κB activity in the absence of wtRac1 (P < 0.001). These findings suggest that Rac1 is required for stimulation of NF-κB activity by SF and wt-Src; and they place Src upstream of Rac1 for NF-κB activation. We next tested the ability of SF and Src to stimulate Rac1 activity, which was assessed indirectly, by measuring the kinase activity of Pak1, a target of Rac1 (30) . DU-145 cells were transfected as indicated, treated ± SF (20 min), and harvested for a Pak1 IP-kinase assay, using MBP as the substrate. SF stimulated Pak1 activity; and wt-Src further enhanced the SFstimulated Pak1 activity (Fig. 9C) . DN-Src inhibited both basal and SF-stimulated Pak1 activity (Fig. 9D) . Similarly, wt-Rac1 enhanced and DN-Rac1 inhibited SF-stimulated Pak1 activity. As controls, the exogenous Src and Rac proteins were well-expressed; and the total Pak1 protein levels remained constant. These findings suggest that SF and Src stimulate Rac1 activity.
Relationship of Akt and Rac1 signaling.
We tested the effects of simultaneously stimulating Akt and inhibiting Rac1 and vice versa on NF-κB activity in DU-145 and MDCK. In SF-treated cells, wt-Akt alone further stimulated NF-κB activity by about 4-fold, while DN-Rac1 alone nearly abrogated the SF-stimulated NF-κB activity (Fig. 10A) . In the presence of (SF+wtAkt+DN-Rac1), the NF-κB activity was lower than in the presence of SF alone. In the converse experiment, wt-Rac1 alone enhanced and DN-Akt alone nearly abrogated the SF-stimulated NF-κB activity (Fig 10B) . The combination (SF+wtRac1+DN-Akt) gave significantly lower NF-κB activity than SF alone (P<0.001). Interestingly, in the absence of SF, DN-Akt was much more effective at inhibiting wt-Rac1-stimulated NF-κB activity than vice versa. These findings suggest that in the c-Met/NF-κB pathway, Akt and Rac1 do not act in a simple series model, but interact in a more complex manner (see Discussion).
Effect of ADR on NF-κB signaling. As described earlier, DN-Src and Src-siRNA decreased NF-κB activity in the absence of SF (Fig. 1) . However, DN-Src (Fig. 2C) and Src-siRNA (Fig. 2G) caused little or no reduction of survival of ADR-treated cells in the absence of SF, suggesting that NF-κB does not contribute significantly to the basal survival of ADR-treated cells in our assay system. To further examine this issue, we tested the effect of ADR on NF-κB activity. DU-145 cells were transfected with the NF-κB-Luc reporter, treated with ADR for 2 hr, and treated ± SF for different times up to 24 hr prior to harvesting for luciferase assays. ADR did not cause any NF-κB activation but did cause some reduction of NF-κB activity to below baseline ( Supplementary Fig. 2 ). SF caused time-dependent increases in NF-κB activity, with the increases being smaller in the presence of ADR than in its absence at most time points (P < 0.01). The finding that ADR does not activate NF-κB is consistent with the observation that inhibition of Src had very little effect on the survival of ADR-treated cells.
Effect of signaling proteins on cell survival.
Since NF-κB may not be the only Src target for protection against ADR, NF-κB reporter assays may not always reflect cell survival. Here, we used survival (MTT) assays as a second biologic readout for various signaling proteins. Studies were carried out at two doses of ADR (15 and 20 µM). The results were qualitatively similar at each dose and in DU-145 vs MDCK cells. First, we tested combinations of wt-MKK3 (or wt-MKK6) and DN-Src and vice versa. wt-MKK3 yielded moderate increases in the survival of ADR-treated cells by itself but gave much larger increases in survival (up to +27%) with SF present (P < 0.001) [Fig. 11A ]. Increases in survival due to SF or (SF+wt-MKK3) were abolished by DN-Src. DN-MKK3 reduced survival to below control levels (± SF) and abrogated the ability of wt-Src to enhance SF protection (Fig. 11B) . Similar results were obtained in parallel studies using wt-MKK6 and DN-MKK6 (data not shown). These results are generally consistent with the NF-κB assays and suggest that MKK3/6 contribute to basal and SFstimulated cell survival.
As expected, wt-Src caused larger increases in survival in the presence of SF than in its absence (Fig. 11C) . DN-TAK1 caused small reductions in survival in the absence of SF but strongly inhibited the ability of SF to protect cells (P < 0.001); and DN-TAK1 abolished the protective activity of (SF+wt-Src) [Fig. 11C ]. Like wt-Src, wt-TAK1 alone caused only a slight increase in survival but significantly enhanced SFstimulated cell survival (Fig. 11D) [P < 0.001]. As before, DN-Src alone caused little or no reduction in cell survival; but DN-Src essentially abrogated the protection due to SF or (SF+wt-TAK1) [P < 0.001]. Experiments using wt-Src/DN-NIK (Fig.  11E ) and wt-NIK/DN-Src (Fig. 11F) gave similar results to those using wt-Src/DN-TAK1 and wt-TAK1/DN-Src.
Effects of inhibition of signal transduction on SF protection against anoikis.
Previous studies show that SF protects cells against apoptosis caused by loss of attachment to a substratum (anoikis) [3, 32] . Here, we tested whether the signal transduction pathways that regulate SF protection against ADR also modulate SF protection against anoikis. Briefly, MDCK cells were transfected with DN and/or wild-type expression vectors, inoculated into dishes coated with a compound to which the cells cannot attach (poly-HEMA), incubated ± SF for 48 hr, and assayed for cell death by the failure to exclude trypan blue dye. Typically, MDCK cells transfected with empty pcDNA3 vector showed 75-80% cell death in the absence of SF; and the cell death rates were reduced to 25% with SF present (P < 0.001) [Fig. 12 ]. Without SF, cell death rates were increased modestly (+3-8%) by DN-MKK3, DN-p38, and DN-Rac1. However, each of these DN proteins increased cell death more substantially (by +34%, +17%, and +34%, respectively) with SF present (Fig. 12A) . Similarly, DN-MKK6, DN-Src, DN-NIK, and DN-TAK1 strongly attenuated SF protection against anoikis (Fig. 12B ). Of the vectors tested, DN-Src caused the largest increase in cell death in the absence of SF (+17%), suggesting that Src contributes to basal survival in this assay.
wt-Src and wt-Rac1 inhibited anoikis with or without SF (Fig. 10C) . In tests of combinations of vectors, (wt-Src+DN-Rac1)-transfected cells showed little or no reduction in cell death compared to cells transfected with DN-Rac1 alone. In contrast, death rates in (wt-Rac1+DN-Src)-transfected cells were similar to those of cells transfected with wt-Rac1 alone. These findings suggest that a Src/Rac1 pathway contributes to protection against anoikis, with Rac1 acting downstream of Src.
DISCUSSION
We studied the role of Src in SF protection and survival signaling. In DU-145 cells, wt-Src and activated mutants enhanced survival of ADRtreated cells without or with SF; but the increased survival due to Src was greater with SF present. Conversely, Src knockdown abrogated SF protection against ADR. Kinase-dead and SH 3 domain mutants behaved like dominant negatives and blocked SF protection. These findings suggest that Src kinase activity and its SH 3 domain (a signaling module that interacts with proline-rich amino acid sequences) [40] are required for protection. Having previously shown that NF-κB is required for SF protection, we used NF-κB reporter assays to probe the mechanisms by which Src signals cell survival.
The IKK complex regulates NF-κB activity by phosphorylating the cytoplasmic inhibitors of NF-κB (IκB proteins), leading to their degradation. Several studies describe a role for Src in IKK activation by the inflammatory cytokines interleukin-1 and tumor necrosis factor-α (TNF-α) [43, 44] ; and another study suggests that Src is a component of the IKK complex and associates with the regulatory subunit IKK-γ (NEMO) [45] . We established that Src in modulates SF-stimulated IKK-β activity. Thus, active Src proteins enhanced, while DN mutant Src proteins blocked SF-stimulated IKK-β activity.
As expected, SF caused an activating phosphorylation of Src (tyrosine-418) and stimulated Src kinase activity. In DU-145 and MDCK cells, active Src proteins stimulated NF-κB activity without or with SF. However, the impact of Src was greater with SF present, since SF stimulated NF-κB activity by (50-70)-fold over the basal activity. These findings suggest that while Src is required for SF protection, Src alone cannot fully activate NF-κB signaling.
NF-κB activation by (SF+wt-Src) or wtSrc alone was strongly attenuated by DN-Akt, indicating that Src activation of NF-κB is Aktdependent. We previously found that Akt is required for NF-κB activation by SF (14) . Roles for Akt in NF-κB activation have been described in other contexts (46, 47) . Thus, in response to TNF-α, Akt mediates IKK-α phosphorylation on serine-23, suggesting that Akt activates the IKK kinase (47) . PTEN inhibits Akt activation via its lipid phosphatase activity (37) . Consistent with this finding, wild-type (but not mutant) PTEN blocked (SF+Src)-induced NF-κB activity.
We identified MKK3 and MKK6 [activators of p38 (26, 38) ] as mediators of SF activation of NF-κB in DU-145 and MDCK cells (48) . Inhibition of p38 blocked SF-stimulated NF-κB activity, suggesting that p38 is the relevant target of MKK3/6. p38 may stimulate NF-κB by enhancing the activity of the p65/RelA subunit (49) and/or stimulating IKK activity. Here, we identified Src and Rac1 as upstream activators of an MKK3/6/p38 pathway that mediates SF activation of the IKK-β kinase and NF-κB. Stimulation of IKK-β activity by SF, Src, and Rac1 was abrogated by p38 inhibition. Biochemical studies revealed that SF caused activating phosphorylations of Src, MKK3, MKK6, and p38 in protein complexes associated with c-Met and with Src and that the phosphorylation of MKK3, MKK6, and p38 were Src-dependent. These findings suggest that SF stimulates Src/MKK3/6/p38 signaling in the c-Met signalsome.
Our findings place Src and Rac1 upstream of MKK3/6/p38 for NF-κB activation by SF and are consistent with reports that Src can activate p38 (50) and stimulate NF-κB (51, 52) in other contexts. Mechanisms by which Src stimulates NF-κB include tyrosine phosphorylation and activation of IKK (43) or inhibition of IκB-α (51).
Several studies suggest a role for a Rac1/MKK3/p38 pathway in cell invasion (45, 52) . Our study suggests that this pathway also mediates NF-κB activity and cell survival.
NIK associates with and activates IKK, leading to phosphorylation of IκB and release of the NF-κB transcriptional subunits (53, 54) . Analysis of Nik -/-mice suggests that NIK is not a universal IKK activator but acts in a receptorspecific manner (55) . In our study, wt-NIK enhanced and DN-NIK or NIK-siRNA inhibited SF-stimulated NF-κB activity, suggesting that NIK contributes to NF-κB activation by SF. TAK1, a potential upstream activator of IKK-β and MKK3/6 (40,41), enhanced SF-stimulated NF-κB activity in an NIK-dependent manner, suggesting that a TAK1/NIK/NF-κB pathway operates in DU-145 and MDCK. Further studies revealed that wt-Src and Rac1 enhanced while DN-Src and DN-Rac1 blocked SF-stimulated Pak1 activity. Previously, we showed that Pak1 is required for SF stimulation of NF-κB and protection against ADR (7, 14) . This study validates a role for Rac1 and Pak1 in SF survival signaling and implicates Src and Rac1 as Pak1 activators in this pathway. However, since Pak1 is a target of other signaling pathways, Rac1 may not be the only mediator of Pak1 activation by SF.
Although
DNA-damaging agents, including anthracyclines, may cause activation of NF-κB (58, 59) , the effects of NF-κB on cell survival are variable; and NF-κB may promote survival, have no effect, or even promote apoptosis in some contexts (60) (61) (62) . While inhibition of Src caused a reduction of basal NF-κB activity, it had little or no effect on the basal cell survival response to ADR in the absence of SF. This finding is consistent with our previous observation that inhibition of NF-κB using an IκB super-repressor caused little or no reduction of basal survival (14) . Consistent with these data, ADR did not stimulate NF-κB signaling. These considerations suggest that in our assays, the basal NF-κB activity is sufficiently low (even though it is detected by reporter assays) that reducing it further with DN-Src or Src-siRNA has a negligible effect on survival.
To determine if Akt and Rac1 act in series to stimulate NF-κB activity as do Src and Rac1, we tested the effects of simultaneously stimulating Akt and inhibiting Rac1 and vice versa. Here, DNRac1 strongly inhibited the (SF+wt-Akt)-stimulated NF-κB activity; and conversely, DNAkt strongly inhibited the (SF+wt-Rac1)-stimulated NF-κB activity. These findings suggest that Akt and Rac1 do not act in series. One possible model is that these proteins act in parallel pathways, both of which are required to activate NF-κB. Alternatively, Akt and Rac1 may interact to confer maximal NF-κB activation.
We identified two pathways (TAK1/NIK and Src/Rac1/MKK3/6/p38) that contribute to SFmediated NF-κB activation. To synthesize these pathways, we studied the role of Src in the TAK1/NIK/ NF-κB pathway and potential interactions of the TAK1/NIK and MKK3/6/p38 pathways. Exogenous Src failed to rescue the inhibition of SF-stimulated NF-κB activity due to inhibition of TAK1 or NIK. Conversely, exogenous TAK1 or NIK failed to rescue the inhibition of SF-stimulated NF-κB activity by DNSrc. These findings suggest cross-talk between the Src/NF-κB and TAK1/NIK/NF-κB pathways so that Src, TAK1, and NIK are all required for SFmediated NF-κB activation. One scenario consistent with our findings is that SF stimulates Src-dependent/TAK1/NIK-dependent and Srcdependent/TAK1/NIK-independent pathways of NF-κB activation. In this scenario, both pathways are required for full SF-stimulated NF-κB activation; and these pathways act synergistically, so that inactivation of either pathway can reduce NF-κB activity to levels only modestly greater than the basal activity.
In studies of the TAK1/NIK vs MKK3/6/p38 pathways, DN-MKK3 and DN-MKK6 each blocked the (SF+wt-TAK1)-stimulated NF-κB activation, although DN-MKK3 was more effective than DN-MKK6 in this respect. However, even in the presence of DN-MKK3, (SF+wt-TAK1) and (SF+wt-NIK) were still able to stimulate NF-κB activity to some extent, consistent with a model in which SF/TAK1/ NIK/NF-κB signaling occurs by MKK3-dependent and MKK3-independent mechanisms. Further studies revealed that inhibition of TAK1 or NIK by siRNAs caused only a modest reduction in the (SF+wt-MKK3)-induced NF-κB activity. The relative inability of TAK1-or NIK-siRNA to block (SF+wt-MKK3)-induced NF-κB activation suggests that for the most part, MKK3 is not upstream of TAK1/ NIK in SF-mediated NF-κB activation.
Since NF-κB may not be the only Src target for SF protection against ADR, we tested the roles of these signaling pathways in the survival response to ADR. Inhibition of transducers for SF-mediated NF-κB activation (TAK1, NIK, and MKK3/6) abrogated SF protection against ADR, indicating that these proteins are required for protection. Conversely, over-expression of each wild-type protein enhanced SF protection. As with Src, overexpression of the wild-type proteins gave only modest increases in survival in the absence of SF, suggesting that these proteins alone cannot fully activate survival signaling. Unlike Src, TAK1, and NIK, inhibition of MKK3 or MKK6 reduced the survival of (SF+ADR)-treated cells to below that for ADR alone. Consistent with the NF-κB assays, DN-Src abrogated the ability of SF plus wt-TAK1 or wt-NIK to stimulate cell survival. But in contrast to NF-κB, wt-MKK3 and wt-MKK6 failed to rescue the inhibition of SF protection by DN-Src. DN-MKK3 and DN-MKK6 each reduced the survival of cells treated with (SF+wt-Src+ADR) to less than that of cells treated with ADR alone. Thus, while the survival assays were usually consistent with NF-κB assays, manipulation of Src may modulate survival in a manner is not always predicted by NF-κB assays. Our findings also suggest that unlike Src, MKK3/6 contribute significantly to the basal survival of DNA-damaged cells, although we cannot rule out the possibility that the DN-MKK3/6 proteins have off-target effects that enhance sensitivity to ADR.
Since other signals that cooperate with cMet may modulate the biologic consequences of cMet activation, we tested whether the signaling pathways for SF protection against DNA damage also mediate protection against anoikis (apoptosis due to loss of contact with the substratum) [3, 32] . Protection against anoikis is due, in part, to an integrin-mediated survival signal via the PI3 kinase/Akt pathway (56, 57) . We found that some of the same signaling proteins involved in SF protection against ADR (Src, Rac1, p38, MKK3/6, NIK, and TAK1) contribute to SF protection against anoikis. However, some differences in survival outcomes were observed. While Src contributed negligibly to survival of ADR-treated cells in the absence of SF, it contributed significantly to protection against anoikis in the absence of SF. In addition, the magnitude of SF protection against anoikis was greater than that of SF protection against ADR, suggesting that the survival signal due to attachment to the extracellular matrix cooperates with that due to cMet ligation or endogenous Src activity.
In toto, our studies suggest three pathways by which Src mediates SF stimulation of NF-κB activity: 1) Src/Akt/IKK/NF-κB; 2) Src/Rac1/ MKK3/6/p38/IKK/NF-κB; and 3) TAK1/NIK/NF-κB. Pathways 1) and 2) appear to exhibit crosstalk through Rac1; while pathways 2) and 3) appear to show cross-talk through MKK3 (see Fig.  13 ). . The wells were washed, postincubated in fresh culture medium ± SF (100 ng/ml) for 24 hr, and harvested for luciferase assays. Luciferase values are expressed relative to control cells (no vector, 0 SF) and are means ± SEMs of four replicate wells. The data shown are representative of at least two independent experiments. B, Effect of Src knockdown on basal and SF-stimulated NF-κB activity. Proliferating cells were pre-incubated with control-siRNA or Src-siRNA (50 nM x 48 hr) and then assayed for basal and SF-stimulated NF-κB-Luc activity as above. C, Src enhances and is required for SF stimulation of IKK-β kinase activity. DU-145 cells were transfected with the indicated vector, washed, allowed to recover for several hr, and treated ± SF (100 ng/ml) for 20 min. The cells were harvested; and IKK-β activity was determined using a commercial assay kit (see Methods section). The IKK-β activity values are means ± SEMs of five replicate wells and are expressed as a percent of the control (no SF, mock transfection). A, Src causes activation (phosphorylation) of p38 and is required for SF-stimulated p38 activation. DU-145 cells were transfected with empty vector (pcDNA3), wt-Src, or a dominant negative Src (K295R); washed; post-incubated for 24 hr to allow gene expression; treated ± SF (100 ng/ml) for 20 min; and harvested for Western blotting to detect Src, phospho-p38, total p38, or α-actin. B, Requirement of MKK3/6 for Src stimulation of NF-κB activity. Proliferating cells in 2-cm 2 wells were transiently co-transfected overnight with the indicated vector(s) and the NF-κB-Luc reporter, washed, post-incubated ± SF (100 ng/ml) for 24 hr, and harvested for luciferase assays. Luciferase values are expressed relative to the negative control (no vector, 0 SF) and are means ± SEMs of four replicate wells. C, Ability of exogenous MKK3 and MKK6 to activate NF-κB in the absence of Src activity. Assays were performed as described for panel C. D, Role of MKK3 and MKK6 in Src-mediated stimulation of IKK-β kinase activity. DU-145 cells were transfected as indicated, washed, allowed to recover for several hr, and treated ± SF (100 ng/ml) for 20 min. The cells were then harvested; and IKK-β activity was determined as described in the Methods section. The IKK-β kinase activity values are means ± SEMs of five replicate wells and are expressed as a percentage of the control value (no SF, mock transfection). Right. Cells were transfected with empty vector, wt-Rac1, or DN-Rac1 (RacN17); washed; post-incubated for 24 hr; treated ± SF (100 ng/ml) for 20 min; and Western blotted for Rac1, phospho-p38, and total p38. 
